{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:16:56Z","timestamp":1773119816635,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201530"],"award-info":[{"award-number":["OPP1201530"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201530"],"award-info":[{"award-number":["OPP1201530"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1201530"],"award-info":[{"award-number":["OPP1201530"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Onchocerciasis is endemic in most local government areas (LGAs) in Enugu and Ogun states. Most meso- and hyper-endemic LGAs have received many rounds of ivermectin mass drug administration (MDA). This study aimed to determine the current prevalence of onchocerciasis in villages in Enugu and Ogun states that were formerly highly endemic and to assess progress toward elimination of the infection in areas believed to be at high risk for persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cross-sectional community surveys were conducted 8 to 12\u00a0months after the last round of MDA in 16 villages (6 in Enugu state and 10 in Ogun state) in individuals aged\u2009\u2265\u200918\u00a0years. Study participants were examined for the presence of palpable subcutaneous nodules. Skin snips from the posterior iliac crests were used to assess microfiladermia (Mf) prevalence and density.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>643 subjects were palpated for nodules and 627 individuals (225 in Enugu state; 402 in Ogun state) provided skin snips. Nodule prevalence in the study villages ranged from 42 to 66.7% in Enugu state and from 0 to 25.0% in Ogun state. Mf prevalence in the Enugu and Ogun study villages ranged from 32 to 51.1% and 0 to 28.6%, respectively. Geometric mean skin Mf density in surveyed Enugu state villages ranged between 1 and 3.1 Mf\/mg; these values were\u2009&lt;\u20091 Mf\/mg in all but one community in Ogun state villages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Results from this study show that onchocerciasis persists in adults in many villages in Enugu and Ogun states despite many prior rounds of ivermectin MDA. Prevalence was higher in villages surveyed in Enugu than in Ogun. Low Mf densities suggest the MDA program is working well to reduce disease, but more time will be required to reach the elimination goal.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07811-7","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T16:05:43Z","timestamp":1668096343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin"],"prefix":"10.1186","volume":"22","author":[{"given":"Uwem F.","family":"Ekpo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obiora A.","family":"Eneanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith N.","family":"Nwankwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islamiat Y.","family":"Soneye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obioma C.","family":"Nwaorgu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"issue":"2","key":"7811_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/trstmh\/trab002","volume":"115","author":"MN Malecela","year":"2021","unstructured":"Malecela MN, Ducker C. A road map for neglected tropical diseases 2021\u20132030. Trans R Soc Trop Med Hyg. 2021;115(2):121\u20133.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"7811_CR2","unstructured":"World Health Organization. Onchocerciasis: symptomatology, pathology, diagnosis. A. A. Buck, editor. Geneva: World Health Organization; 1974."},{"issue":"10","key":"7811_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0277-9536(99)00389-5","volume":"50","author":"C Vlassoff","year":"2000","unstructured":"Vlassoff C, Weiss M, Ovuga EB, Eneanya C, Nwel PT, Babalola SS, et al. Gender and the stigma of onchocercal skin disease in Africa. Soc Sci Med. 2000;50(10):1353\u201368.","journal-title":"Soc Sci Med"},{"issue":"Suppl 1","key":"7811_CR4","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1080\/00034983.1998.11813370","volume":"92","author":"EI Gemade","year":"1998","unstructured":"Gemade EI, Jiya JY, Nwoke BE, Ogunba EO, Edeghere H, Akoh JI, et al. Human onchocerciasis: current assessment of the disease burden in Nigeria by rapid epidemiological mapping. Ann Trop Med Parasitol. 1998;92(Suppl 1):S79-83.","journal-title":"Ann Trop Med Parasitol"},{"key":"7811_CR5","unstructured":"World Health Organization. Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. Ouagadougou: African Programme for Onchocerciasis Control; 2010 2010. Contract No.: JAF16.6(II)."},{"issue":"10154","key":"7811_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","volume":"392","author":"NO Opoku","year":"2018","unstructured":"Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018;392(10154):1207\u201316.","journal-title":"Lancet"},{"issue":"4","key":"7811_CR7","first-page":"256","volume":"43","author":"DC Chavasse","year":"1992","unstructured":"Chavasse DC, Post RJ, Lemoh PA, Whitworth JA. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop Med Parasitol. 1992;43(4):256\u201362.","journal-title":"Trop Med Parasitol"},{"key":"7811_CR8","unstructured":"Federal Ministry of Health. Neglected Tropical Diseases\u2014Nigeria multi-year master plan 2015\u20132020 Abuja: Federal Ministry of Health; 2015."},{"key":"7811_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.11604\/pamj.2015.20.397.5686","volume":"20","author":"PN Okorie","year":"2015","unstructured":"Okorie PN, Davies E, Ogunmola OO, Ojurongbe O, Saka Y, Okoeguale B, et al. Lymphatic filariasis baseline survey in two sentinel sites of Ogun state, Nigeria. Pan Afr Med J. 2015;20:397.","journal-title":"Pan Afr Med J."},{"issue":"1","key":"7811_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s13071-019-3682-6","volume":"12","author":"OA Eneanya","year":"2019","unstructured":"Eneanya OA, Fronterre C, Anagbogu I, Okoronkwo C, Garske T, Cano J, et al. Mapping the baseline prevalence of lymphatic filariasis across Nigeria. Parasit Vectors. 2019;12(1):440.","journal-title":"Parasit Vectors"},{"issue":"1","key":"7811_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005163","volume":"11","author":"PU Fischer","year":"2017","unstructured":"Fischer PU, King CL, Jacobson JA, Weil GJ. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLoS Negl Trop Dis. 2017;11(1): e0005163.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"7811_CR12","first-page":"2","volume":"32","author":"RW Crosskey","year":"1981","unstructured":"Crosskey RW. A review of Simulium damnosum s.l. and human onchocerciasis in Nigeria, with special reference to geographical distribution and the development of a Nigerian national control campaign. Tropenmed Parasitol. 1981;32(1):2\u201316.","journal-title":"Tropenmed Parasitol."},{"issue":"3","key":"7811_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1179\/000349804225003253","volume":"98","author":"K Awadzi","year":"2004","unstructured":"Awadzi K, Boakye DA, Edwards G, Opoku NO, Attah SK, Osei-Atweneboana MY, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98(3):231\u201349.","journal-title":"Ann Trop Med Parasitol"},{"issue":"1","key":"7811_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40249-018-0446-z","volume":"7","author":"Y Dadzie","year":"2018","unstructured":"Dadzie Y, Amazigo UV, Boatin BA, S\u00e9k\u00e9t\u00e9li A. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes. Infect Dis Poverty. 2018;7(1):63.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"7811_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1475-2883-2-8","volume":"2","author":"GJ Borsboom","year":"2003","unstructured":"Borsboom GJ, Boatin BA, Nagelkerke NJ, Agoua H, Akpoboua KL, Alley EW, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination\/eradication in West-Africa. Filaria J. 2003;2(1):8.","journal-title":"Filaria J"},{"issue":"1384","key":"7811_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1098\/rstb.1999.0433","volume":"354","author":"MG Bas\u00e1\u00f1ez","year":"1999","unstructured":"Bas\u00e1\u00f1ez MG, Boussinesq M. Population biology of human onchocerciasis. Philos Trans R Soc Lond B Biol Sci. 1999;354(1384):809\u201326. https:\/\/doi.org\/10.1098\/rstb.1999.0433.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"7811_CR17","first-page":"145","volume":"8","author":"J Eyo","year":"2013","unstructured":"Eyo J, Onyishi G, Ugokwe C. Rapid epidemiological assessment of onchocerciasis in a tropical semi-urban community, Enugu State, Nigeria. Iran J Parasitol. 2013;8(1):145\u201351.","journal-title":"Iran J Parasitol."},{"issue":"1\u20132","key":"7811_CR18","first-page":"413","volume":"59","author":"L Brabin","year":"1990","unstructured":"Brabin L. Factors affecting the differential susceptibility of males and females to onchocerciasis. Acta Leiden. 1990;59(1\u20132):413\u201326.","journal-title":"Acta Leiden"},{"key":"7811_CR19","volume-title":"Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures. Geneva: World Health Organization; 2016."},{"issue":"7","key":"7811_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000497","volume":"3","author":"L Diawara","year":"2009","unstructured":"Diawara L, Traor\u00e9 MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3(7): e497.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"7811_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","volume":"18","author":"P Milton","year":"2020","unstructured":"Milton P, Hamley JID, Walker M, Bas\u00e1\u00f1ez MG. Moxidectin: an oral treatment for human onchocerciasis. Expert Rev Anti Infect Therapy. 2020;18(11):1067\u201381.","journal-title":"Expert Rev Anti Infect Therapy"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07811-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T16:05:53Z","timestamp":1668096353000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07811-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7811"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07811-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments in this present study were approved by the Scientific and Ethical Review Boards of both Ogun and Enugu state Ministries of Health (HPRS\/381\/385). The study was performed in accordance with the Declaration of Helsinki and relevant regulations (ethics approval and consent to participate). In addition, the objectives of the study were discussed with participants and signed informed consent forms were obtained from all participants. Village chiefs and community leaders were sensitized and informed about the study prior to visits by field teams. These leaders selected days for the surveys that were suitable and convenient for their communities. Participation was entirely voluntary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"832"}}